NEW YORK — AstraZeneca shares fell nearly 3 percent at the open Monday following reports of merger talks with Bristol Myers Squibb. The potential deal, valued at $400 billion, has prompted sharp questions from Wall Street analysts about its strategic rationale for AstraZeneca.
Details of the discussions remain scarce, with sources indicating a deal may not materialize.
Analysts said they could not see why AstraZeneca would pursue such a transaction. The company's market value has surged under CEO Pascal Soriot, driven by a strong drug pipeline and consistent product execution.
Portfolio manager Lukas Leu said a combined entity would struggle to position competing drugs within a single portfolio. He said he opposes mega-mergers, citing concerns about their effect on corporate agility.
AstraZeneca's trajectory, built on strong drug development capabilities, has positioned it well in the pharmaceutical sector—making the rationale for a large-scale acquisition unclear to many investors.
The proposed merger would reportedly strengthen AstraZeneca's presence in the United States market.
The prospect of such a deal has also heightened concern in Britain over whether more of the country's largest companies are shifting operations away from the U.K. That sentiment follows AstraZeneca's direct listing in New York in June, a move some characterized as a blow to the London Stock Exchange.
The broader market rose Monday, with the Dow Jones gaining 0.9 percent to 52,971 and the S&P 500 up 1.3 percent to 7,587. AstraZeneca's decline stood out against that positive backdrop.
